{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:58:26Z","timestamp":1790456306535,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03710-4","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:33:28Z","timestamp":1790408008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Patterns in Patients with Spinal Muscular Atrophy Receiving Multiple Disease-Modifying Therapies"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5369-497X","authenticated-orcid":false,"given":"Walter","family":"Toro Jimenez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongni","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Lemus Wirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Reyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"1","key":"3710_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"1","key":"3710_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Prim. 2022;8(1):52.","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"3710_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3710_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamapediatrics.2024.1911","volume":"178","author":"L Belter","year":"2024","unstructured":"Belter L, Taylor JL, Jorgensen E, Glascock J, Whitmire SM, Tingey JJ, et al. Newborn screening and birth prevalence for spinal muscular atrophy in the US. JAMA Pediatr. 2024;178(9):946\u20139.","journal-title":"JAMA Pediatr"},{"issue":"8","key":"3710_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027\u201349.","journal-title":"J Child Neurol"},{"issue":"1","key":"3710_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genom Hum Genet. 2020;21(1):231\u201361.","journal-title":"Annu Rev Genom Hum Genet"},{"issue":"10","key":"3710_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","volume":"27","author":"EF Tizzano","year":"2017","unstructured":"Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul Disord. 2017;27(10):883\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3710_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0724-z","volume":"12","author":"C Lally","year":"2017","unstructured":"Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States. Orphanet J Rare Dis. 2017;12(1):175.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3710_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2011.09.001","volume":"46","author":"JA Markowitz","year":"2012","unstructured":"Markowitz JA, Singh P, Darras BT. Spinal muscular atrophy: a clinical and research update. Pediatr Neurol. 2012;46(1):1\u201312.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"3710_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","volume":"51","author":"WD Arnold","year":"2015","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: Diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51(2):157\u201367.","journal-title":"Muscle Nerve"},{"key":"3710_CR11","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: SPINRAZA (nusinersen) [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf. Accessed 11 Aug 2025."},{"key":"3710_CR12","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: ZOLGENSMA (onasemnogene abeparvovec) [Available from: https:\/\/www.fda.gov\/media\/126109\/download?attachment. Accessed 11 Aug 2025."},{"key":"3710_CR13","unstructured":"United States Food and Drug Administration. FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy 2025 [Available from: https:\/\/www.fda.gov\/media\/189857\/download?attachment. Accessed 11 Aug 2025."},{"key":"3710_CR14","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: EVRYSDI (risdiplam) [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213535s003s005lbl.pdf. Accessed 11 Aug 2025."},{"issue":"18","key":"3710_CR15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"3710_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","volume":"68","author":"TO Crawford","year":"2023","unstructured":"Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve. 2023;68(2):157\u201370.","journal-title":"Muscle Nerve"},{"issue":"4","key":"3710_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"7","key":"3710_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834\u201341.","journal-title":"JAMA Neurol"},{"issue":"5","key":"3710_CR19","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui M, Day JW, Deconinck N, Mazzone ES, Nascimento A, Saito K, et al. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol. 2023;270(5):2531\u201346.","journal-title":"J Neurol"},{"issue":"1","key":"3710_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42\u201352.","journal-title":"Lancet Neurol"},{"issue":"12","key":"3710_CR21","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, Servais L, Xiong H, Zanoteli E, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110\u20139.","journal-title":"Lancet Neurol"},{"key":"3710_CR22","unstructured":"CureSMA. State of SMA 2024 [Available from: https:\/\/www.curesma.org\/wp-content\/uploads\/2025\/04\/State-of-SMA-Report2024_vWeb-4.pdf. Accessed 11 Aug 2025."},{"issue":"2","key":"3710_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/JND-230122","volume":"11","author":"L Servais","year":"2024","unstructured":"Servais L, Day JW, De Vivo DC, Kirschner J, Mercuri E, Muntoni F, et al. Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: Findings from the RESTORE registry. J Neuromuscul Dis. 2024;11(2):425\u201342.","journal-title":"J Neuromuscul Dis"},{"key":"3710_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11101515","author":"D Krupa","year":"2023","unstructured":"Krupa D, Czech M, Chudzy\u0144ska E, Ko\u0144 B, Kostera-Pruszczyk A. Real world evidence on the effectiveness of nusinersen within the national program to treat spinal muscular atrophy in Poland. Healthcare (Basel). 2023. https:\/\/doi.org\/10.3390\/healthcare11101515.","journal-title":"Healthcare (Basel)"},{"key":"3710_CR25","doi-asserted-by":"crossref","unstructured":"Pera MC, Coratti G, Pane M, Masson R, Sansone VA, D\u2019Amico A, et al. Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016. eClinMed. 2024;78:102967.","DOI":"10.1016\/j.eclinm.2024.102967"},{"key":"3710_CR26","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S172291","author":"T Dangouloff","year":"2019","unstructured":"Dangouloff T, Servais L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther Clin Risk Manag. 2019. https:\/\/doi.org\/10.2147\/TCRM.S172291.","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"3710_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","volume":"16","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy\u2014insights and challenges in the treatment era. Nat Rev Neurol. 2020;16(12):706\u201315.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"3710_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJMoa2410120","volume":"393","author":"RS Finkel","year":"2025","unstructured":"Finkel RS, Servais L, Vlodavets D, Zanoteli E, Mazurkiewicz-Be\u0142dzi\u0144ska M, Jong Y-J, et al. Risdiplam in presymptomatic spinal muscular atrophy. N Engl J Med. 2025;393(7):671\u201382.","journal-title":"N Engl J Med"},{"issue":"6","key":"3710_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","volume":"178","author":"O Schwartz","year":"2024","unstructured":"Schwartz O, Vill K, Pfaffenlehner M, Behrens M, Wei\u00df C, Johannsen J, et al. Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial. JAMA Pediatr. 2024;178(6):540\u20137.","journal-title":"JAMA Pediatr"},{"issue":"1","key":"3710_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200374","volume":"15","author":"MK Schroth","year":"2025","unstructured":"Schroth MK, Deans J, Bharucha Goebel DX, Burnette WB, Darras BT, Elsheikh BH, et al. Spinal muscular atrophy update in best practices. Neurol Clin Prac. 2025;15(1):e200374.","journal-title":"Neurol Clin Prac"},{"issue":"2","key":"3710_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","volume":"23","author":"CJJ Yeo","year":"2024","unstructured":"Yeo CJJ, Tizzano EF, Darras BT. Challenges and opportunities in spinal muscular atrophy therapeutics. Lancet Neurol. 2024;23(2):205\u201318.","journal-title":"Lancet Neurol"},{"issue":"1","key":"3710_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/13696998.2019.1646263","volume":"23","author":"M Droege","year":"2020","unstructured":"Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020;23(1):70\u20139.","journal-title":"J Med Econ"},{"key":"3710_CR33","unstructured":"R Core Team (2023). _R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/. Accessed 11 Aug 2025."},{"issue":"10","key":"3710_CR34","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1007\/s12325-023-02621-y","volume":"40","author":"W Toro","year":"2023","unstructured":"Toro W, Yang M, Georgieva M, Song W, Patel A, Jiang A, et al. Health care resource utilization and costs for patients with spinal muscular atrophy: findings from a retrospective US claims database analysis. Adv Ther. 2023;40(10):4589\u2013605.","journal-title":"Adv Ther"},{"key":"3710_CR35","doi-asserted-by":"crossref","unstructured":"Valentini I, Ghetti G, Pane M, Rumi F, Di Brino E, Basile M, et al. Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy. Eur J Health Econ. 2025;27:1\u201318.","DOI":"10.1007\/s10198-025-01806-2"},{"key":"3710_CR36","unstructured":"Belter L, Curry M, Grove E, MS. 2023 Cure SMA Community Update Survey: Patient and Caregiver Reported Rationale for Combination and Sequential Therapy. Muscular Dystrophy Association Clinical and Scientific Conference. Poster Number: T389 [Available from: https:\/\/www.mdaconference.org\/abstract-library\/2023-cure-sma-community-update-survey-patient-and-caregiver-reported-rationale-for-combination-and-sequential-therapy\/. Accessed 11 Aug 2025."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03710-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03710-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03710-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:02:51Z","timestamp":1790452971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03710-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":36,"alternative-id":["3710"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03710-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Walter Toro Jimenez, John Meehan, and Sandra P. Reyna are employees of Novartis Pharmaceuticals Corporation and hold stock\/options. Min Yang, Wei Song, Esteban Lemus Wirtz, and Dongni Ye are employees of Analysis Group, Inc., which has received consulting fees from Novartis Pharmaceuticals Corporation for the conduct of this study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study were de-identified and complied with the confidentiality requirements of the Health Insurance Portability and Accountability Act; therefore, no ethical review was required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}